Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of Cardiology
Surgical Specialties (Canada) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · +52 more institutions
Abstract
Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention…
Citation impact
- FWCI
- 37.53
- Percentile
- 100%
- References
- 156
Authors
40- MMMarco Metra
Surgical Specialties (Canada), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia
- DTDaniela Tomasoni
Surgical Specialties (Canada), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia
- MAMarianna AdamoCorresponding
Surgical Specialties (Canada), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia
- ABAntoni Bayés‐Genís
Universitat Autònoma de Barcelona, Hospital Universitari Germans Trias i Pujol
- GFGerasimos Filippatos
National and Kapodistrian University of Athens
Topics & keywords
- Medicine
- Heart failure
- Intensive care medicine
- Guideline
- Diuretic
- Epidemiology
- Internal medicine
- Pathology
Funding
- ALAbbott Laboratories
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZenecaAward: RE/18/6/34217
- SSanofi
- APAlnylam Pharmaceuticals
- HHelsinn
- BSBoston Scientific Corporation
- DZDeutsches Zentrum für Herz-Kreislaufforschung
- LLivaNova
- CCytokinetics
- RMReCor Medical
- MMyoKardia
- IDImpulse Dynamics
- MModerna
- BHBritish Heart FoundationAwards: 18/6/34217, RE/18/6/34217
- ECEuropean Commission
- UOUniversity of Glasgow
- QUQueen's University Belfast
- DFDeutsche ForschungsgemeinschaftAwards: TTR 219, 322900939
- MDMinistero della SaluteAward: PNRR-MAD-2022-12376632
- QUQueen's University
- GRGedeon Richter
- KIKarolinska Institutet
- NNNovo Nordisk
- SLStockholms Läns LandstingAwards: 20170112, 20190525
- VVetenskapsrådetAward: 523-2014-2336
- VPVifor Pharma
- SServier
- IPIdorsia Pharmaceuticals
- CPChugai Pharmaceutical
- AVAbbott Vascular
- RRespicardia
- RRelypsa